Patent application number | Description | Published |
20090088086 | MODIFIED DUAL BAND DIRECT CONVERSION ARCHITECTURE THAT ALLOWS EXTENSIVE DIGITAL CALIBRATION - A communication device may include one or more circuits in an integrated transmitter and receiver that includes a transmit path and a receive path. The transmit path may include an I processing baseband transmit path and a Q processing baseband transmit path. The receive path may include an I processing baseband receive path and a Q processing baseband receive path. The one or more circuits may enable sharing a first common filter by the I processing baseband transmit path and the I processing baseband receive path. The one or more circuits may also enable sharing a second common filter by the Q processing baseband transmit path and the Q processing baseband receive path. The first common filter and the second common filter are independently programmable to adjust a phase and/or a gain of the said first common filter, and/or a phase and/or a gain of the second common filter. | 04-02-2009 |
20100015936 | METHOD AND SYSTEM FOR MEASURING RECEIVER MIXER IQ MISMATCH - A system for correcting an IQ mismatch in a receiver mixer is disclosed and may include one or more circuits that generate an IQ correlation with a training signal having periodic, uncorrelated I and Q signals. The one or more circuits may estimate a gain mismatch based on a power estimate of the periodic, uncorrelated I and Q signals over a unit period. The one or more circuits may estimate a phase mismatch based on the IQ correlation over the unit period, and may apply at least one correction parameter to the receiver mixer. The at least one correction parameter may be based on the gain mismatch estimate and the phase mismatch estimate. The one or more circuits may provide the training signal on a closed RF signal path between a transmitter and the receiver mixer, and may estimate the IQ mismatch iteratively. | 01-21-2010 |
20100233971 | DIRECT-CONVERSION TRANSCEIVER ENABLING DIGITAL CALIBRATION - A method for calibrating a transceiver includes selecting one of a plurality of available calibration paths on the transceiver to be active. The transceiver includes a transmitter and a receiver. The selected one of the plurality of available calibration paths couples the transmitter to the receiver through a circuit that is external to the transceiver. A calibration signal may be provided to enable calibration of the transceiver via the selected one of the plurality of available calibration paths. The calibration signal may be received after it has passed through the selected one of the plurality of calibration paths. Characteristics of the transceiver may be measured using the received calibration signal. | 09-16-2010 |
20110312292 | METHOD AND SYSTEM FOR MEASURING RECEIVER MIXER IQ MISMATCH - A system for correcting a mismatch between an in-phase path and a quadrature path in a receiver, the system including one or more processors operable to correlate a received signal with a complex training sequence having periodic, uncorrelated real and imaginary components, thereby generating a complex correlation. The one or more processors estimate a gain mismatch and a phase mismatch based on the complex correlation over a unit period. The one or more processors control a first receive filter in the in-phase path via a first digital-to-analog controller, and control a second receive filter in the quadrature path via a second digital-to-analog controller. The cutoff frequency and bandwidth of the first receive filter is controlled independently of the second receive filter to enable the output of the first receive filter and the output of the second receive filter to be tightly matched. | 12-22-2011 |
Patent application number | Description | Published |
20100143368 | Human Antibodies That Bind Cd22 And Uses Thereof - The present disclosure provides isolated monoclonal antibodies that specifically bind to CD22 with high affinity, particularly human monoclonal antibodies. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Antibody-partner molecule conjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for detecting CD22, as well as methods for treating various cancers and inflammatory and autoimmune disorders using an anti-CD22 antibody of this disclosure. | 06-10-2010 |
20100150950 | HUMAN ANTIBODIES THAT BIND CD70 AND USES THEREOF - The present disclosure provides isolated monoclonal antibodies that specifically bind to CD70 with high affinity, particularly human monoclonal antibodies. Preferably, the antibodies bind human CD70. In certain embodiments, the antibodies are capable of being internalized into CD70-expressing cells or are capable of mediating antigen dependent cellular cytotoxicity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Antibody-partner molecule conjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for detecting CD70, as well as methods for treating cancers, such as renal cancer and lymphomas, using an anti-CD7Q antibody of this disclosure. | 06-17-2010 |
20100209432 | MONOCLONAL ANTIBODIES AGAINST GLYPICAN-3 - The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to Glypican-3 with high affinity. Nucleic acid molecules encoding Glypican-3 antibodies, expression vectors, host cells and methods for expressing the Glypican-3 antibodies are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the Glypican-3 antibodies are also provided. Methods for detecting Glypican-3, as well as methods for treating various Glypican-3-related conditions, including hepatocellular cancer, are disclosed. | 08-19-2010 |
20100330078 | ALPHA 5 - BETA 1 ANTIBODIES AND THEIR USES - The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies, or antigen binding portions thereof, that specifically bind to integrin α5β1 with high affinity. Nucleic acid molecules encoding the antibodies of the disclosure, expression vectors, host cells and methods for expressing the antibodies of the disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies or antigen binding portions thereof are also provided. The disclosure also provides methods for treating various cancers using the anti-α5β1 antibodies or antigen binding portions thereof described herein. | 12-30-2010 |
20110150892 | HUMAN ANTIBODIES THAT BIND LYMPHOCYTE ACTIVATION GENE-3 (LAG-3) AND USES THEREOF - The present disclosure provides isolated monoclonal antibodies that specifically bind to LAG-3 with high affinity, particularly human monoclonal antibodies. Preferably, the antibodies bind human LAG-3. In certain embodiments, the antibodies bind both human and monkey LAG-3 but do not bind mouse LAG-3. The invention provides anti-LAG-3 antibodies that can inhibit the binding of LAG-3 to MHC Class II molecules and that can stimulate antigen- specific T cell responses. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. This disclosure also provides methods for detecting LAG-3, as well as methods for treating stimulating immune responses using an anti-LAG-3 antibody of the invention. Combination therapy, in which an anti- LAG-3 antibody is co-administered with at least one additional immuno stimulatory antibody, is also provided. | 06-23-2011 |
20120009622 | ALPHA5-BETA1 ANTIBODIES AND THEIR USES - The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies, or antigen binding portions thereof, that specifically bind to integrin α5β1 with high affinity. Nucleic acid molecules encoding the antibodies of the disclosure, expression vectors, host cells and methods for expressing the antibodies of the disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies or antigen binding portions thereof are also provided. The disclosure also provides methods for treating various cancers using the anti-α5β1 antibodies or antigen binding portions thereof described herein. | 01-12-2012 |
20130230530 | HUMAN ANTIBODIES THAT BIND CD22 AND USES THEREOF - The present disclosure provides isolated monoclonal antibodies that specifically bind to CD22 with high affinity, particularly human monoclonal antibodies. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Antibody-partner molecule conjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for detecting CD22, as well as methods for treating various cancers and inflammatory and autoimmune disorders using an anti-CD22 antibody of this disclosure. | 09-05-2013 |
20140154268 | ALPHA5-BETA1 ANTIBODIES AND THEIR USES - The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies, or antigen binding portions thereof, that specifically bind to integrin α5β1 with high affinity. Nucleic acid molecules encoding the antibodies of the disclosure, expression vectors, host cells and methods for expressing the antibodies of the disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies or antigen binding portions thereof are also provided. The disclosure also provides methods for treating various cancers using the anti-α5β1 antibodies or antigen binding portions thereof described herein. | 06-05-2014 |
20140186892 | MONOCLONAL ANTIBODIES AGAINST GLYPICAN-3 - The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to Glypican-3 with high affinity. Nucleic acid molecules encoding Glypican-3 antibodies, expression vectors, host cells and methods for expressing the Glypican-3 antibodies are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the Glypican-3 antibodies are also provided. Methods for detecting Glypican-3, as well as methods for treating various Glypican-3-related conditions, including hepatocellular cancer, are disclosed. | 07-03-2014 |
Patent application number | Description | Published |
20090140349 | SEMICONDUCTOR INTEGRATED CIRCUIT DEVICE AND PROCESS FOR MANUFACTURING THE SAME - A SRAM of complete CMOS type having its memory cell composed of six MISFETs, in which a pair of local wiring lines for connecting the input/output terminals of CMOS inverters are formed of a refractory metal silicide layer formed over a first conducting layer constituting the individual gate electrodes of the drive MISFETs, the transfer MISFETs and the load MISFETs of the memory cell and in which a reference voltage line formed over the local wiring lines is arranged to be superposed over the local wiring lines to form a capacity element. Moreover, the capacity element is formed between the local wiring lines and the first conducting layer by superposing the local wiring lines over the first conducting layer. Moreover, the local wiring lines are formed by using resistance lowering means such as silicification. In addition, there are made common the means for lowering the resistance of the gate electrode of the transfer MISFETs and the means for forming the local wiring lines. | 06-04-2009 |
20110076820 | SEMICONDUCTOR INTEGRATED CIRCUIT DEVICE AND PROCESS FOR MANUFACTURING THE SAME - A SRAM of complete CMOS type having its memory cell composed of six MISFETs, in which a pair of local wiring lines for connecting the input/output terminals of CMOS inverters are formed of a refractory metal silicide layer formed over a first conducting layer constituting the individual gate electrodes of the drive MISFETs, the transfer MISFETs and the load MISFETs of the memory cell and in which a reference voltage line formed over the local wiring lines is arranged to be superposed over the local wiring lines to form a capacity element. Moreover, the capacity element is formed between the local wiring lines and the first conducting layer by superposing the local wiring lines over the first conducting layer. Moreover, the local wiring lines are formed by using resistance lowering means such as silicification. In addition, there are made common the means for lowering the resistance of the gate electrode of the transfer MISFETs and the means for forming the local wiring lines. | 03-31-2011 |
20110156155 | SEMICONDUCTOR INTEGRATED CIRCUIT DEVICE AND PROCESS FOR MANUFACTURING THE SAME - A SRAM of complete CMOS type having its memory cell composed of six MISFETs, in which a pair of local wiring lines for connecting the input/output terminals of CMOS inverters are formed of a refractory metal silicide layer formed over a first conducting layer constituting the individual gate electrodes of the drive MISFETs, the transfer MISFETs and the load MISFETs of the memory cell and in which a reference voltage line formed over the local wiring lines is arranged to be superposed over the local wiring lines to form a capacity element. Moreover, the capacity element is formed between the local wiring lines and the first conducting layer by superposing the local wiring lines over the first conducting layer. Moreover, the local wiring lines are formed by using resistance lowering means such as silicification. In addition, there are made common the means for lowering the resistance of the gate electrode of the transfer MISFETs and the means for forming the local wiring lines. | 06-30-2011 |
20110159653 | SEMICONDUCTOR INTEGRATED CIRCUIT DEVICE AND PROCESS FOR MANUFACTURING THE SAME - A SRAM of complete CMOS type having its memory cell composed of six MISFETs, in which a pair of local wiring lines for connecting the input/output terminals of CMOS inverters are formed of a refractory metal silicide layer formed over a first conducting layer constituting the individual gate electrodes of the drive MISFETs, the transfer MISFETs and the load MISFETs of the memory cell and in which a reference voltage line formed over the local wiring lines is arranged to be superposed over the local wiring lines to form a capacity element. Moreover, the capacity element is formed between the local wiring lines and the first conducting layer by superposing the local wiring lines over the first conducting layer. Moreover, the local wiring lines are formed by using resistance lowering means such as silicification. In addition, there are made common the means for lowering the resistance of the gate electrode of the transfer MISFETs and the means for forming the local wiring lines. | 06-30-2011 |